Dicerna Pharmaceuticals, Inc. (DRNA) was a big mover last session, as its shares rose almost 20% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the healthcare company, as the stock is now up over 41% in the past one-month timeframe.
In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Dicerna Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Other better-ranked stocks in the medical sector include Affymetrix Inc. (AFFX), ANI Pharmaceuticals, Inc. (ANIP) and Actelion Ltd. (ALIOF). While Affymetrix carries a Zacks Rank #2 (Buy), ANI Pharmaceuticals and Actelion sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
DICERNA PHARMACEUTICALS INC (DRNA): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry
- Finance Trading